<!doctype html><html lang="en" style="--width: 728px;
        --height: 90px;
        --hcp-disclaimer-font-size: 8px;
        --hcp-disclaimer-top: 58px;
        --hcp-disclaimer-left: 9px;
        --title-font-size: 20px"><head><meta charset="UTF-8"><meta name="viewport" content="width=device-width,user-scalable=no,initial-scale=1,maximum-scale=1,minimum-scale=1"><meta http-equiv="X-UA-Compatible" content="ie=edge"><title>Ad Banners</title><script>window.mode = "production";</script><script defer="defer" src="main.js"></script><link href="main.css" rel="stylesheet"></head><body><div id="container" class="container container-leaderboard" data-href="pi.pdf"><main id="carousel" data-slide-index="0" style="background-image: url('background.jpg')"><section data-slide-index="0" data-timeout="3000" style="background-color:;"><h2 class="prelude"><span>EVRENZO (roxadustat) is </span><span>indicated for treatment of adult patients with symptomatic </span>anaemia associated with CKD<sup>1</sup></h2><h1 class="title">In anaemia of chronic kidney disease (CKD), the treatment landscape is changing</h1><div class="hcp-disclaimer">For Healthcare Professionals Only<br><span class="highlight-primary">Click here for UK Prescribing Information and Adverse <span>Event Reporting</span></span></div></section><section data-slide-index="1" data-timeout="4000" style="background-color:;"><h1 class="title">Follow a new pathway to treat anaemia of CKD…</h1><div class="hcp-disclaimer">For Healthcare Professionals Only<br><span class="highlight-primary">Click here for UK Prescribing Information and Adverse <span>Event Reporting</span></span></div></section><section data-slide-index="2" data-timeout="3000" style="background-color: #007A33;"><h1 class="title"><span>EVRENZO™</span> harnesses the HIF pathway to stimulate erythropoiesis<sup>1,2</sup></h1><ul><li>HIF (hypoxia-inducible factor) is a central regulator of erythropoiesis<sup>3</sup></li><li>EVRENZO is the first treatment to activate the HIF pathway<sup>4</sup></li><li>Through this action, EVRENZO mimics the body’s natural response to hypoxia<sup>2</sup></li></ul><div class="hcp-disclaimer">For Healthcare Professionals Only<br><span class="highlight-primary">Click here for UK Prescribing Information and Adverse <span>Event Reporting</span></span></div></section><section data-slide-index="3" data-timeout="3000" style="background-color: #007A33;"><div class="grid"><img src="astellas-logo.svg" alt="Astellas"><ol><li>EVRENZO SmPC.</li><li>Del Vecchio L, LocateIIi F. Expert Opin Investig Drugs. 2018;27(1):125-133.</li><li>Locatelli F et al. Am J Nephrol. 2017;45:187-199.</li><li>Sanghani NS, Haase VH. Adv Chronic Kidney Dis 2019; 26:253–266.</li></ol></div><div class="hcp-disclaimer">For Healthcare Professionals Only<br><span class="highlight-primary">Click here for UK Prescribing Information and Adverse <span>Event Reporting</span></span></div></section><section data-slide-index="4" data-timeout="2000" style="background-color: #007A33;"><div class="grid"><img src="astellas-logo.svg" alt="Astellas"><div class="disclaimer"><p>This advert is intended for UK and EU audience only.</p><p>Please note that indications and availability may vary in different countries.</p><p><a class="underline" href="https://www.medicines.org.uk/emc/product/12835" target="_blank" rel="noreferrer">Refer to your local summary of product characteristics/</a> prescribing information for details.</p></div></div><div class="hcp-disclaimer">For Healthcare Professionals Only<br><span class="highlight-primary">Click here for UK Prescribing Information and Adverse <span>Event Reporting</span></span></div></section></main><aside><img src="evrenzo-logo.svg" alt="Evrenzo roxadustat"><div class="legal"><small>EVZ_2021_0131_UK OCTOBER 2021</small></div></aside></div></body></html>